Samsung Biologics’ Kasper Øland discusses why biopharma's shift to complex molecules is redefining what biotech companies require from CDMO partners
As biologics pipelines grow more complex, so do the expectations of CDMO partners. In this BioPharm International interview from BIO 2026, Samsung Biologics' Kasper Øland explores a pivotal industry shift: biotechs no longer want vendors — they want true partners embedded in their teams.
With complex molecules like bispecifics and ADCs now comprising over 55% of our pipeline, Samsung Biologics has responded with platform-based development capabilities that accelerate timelines and reduce risk. Øland shares how tailored platforms, transparency, and customer-centric service are redefining what it means to deliver from IND to commercialization.
Watch the full interview to learn how partnership drives speed without compromise.
As biologics pipelines grow more complex, so do the expectations of CDMO partners. In this BioPharm International interview from BIO 2026, Samsung Biologics' Kasper Øland explores a pivotal industry shift: biotechs no longer want vendors — they want true partners embedded in their teams.
With complex molecules like bispecifics and ADCs now comprising over 55% of our pipeline, Samsung Biologics has responded with platform-based development capabilities that accelerate timelines and reduce risk. Øland shares how tailored platforms, transparency, and customer-centric service are redefining what it means to deliver from IND to commercialization.
Watch the full interview to learn how partnership drives speed without compromise.
Share article
Related Content